drug_type
RELEVANT_DRUG
intervention_type
Biological (CAR T-cell therapy)
drug_description
An autologous, gene‑modified cellular immunotherapy consisting of CD19‑directed CAR T cells that incorporate an anti‑CD19 scFv with 4‑1BB costimulatory and CD3ζ signaling domains. Engagement of CD19 on B cells triggers T‑cell activation, proliferation, and cytotoxic killing of CD19+ leukemic blasts; the 4‑1BB domain supports expansion and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Tisagenlecleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD19-directed CAR T cells bearing an anti-CD19 scFv with 4-1BB costimulatory and CD3ζ signaling domains; engagement of CD19 on B cells activates the CAR T cells, driving proliferation and cytotoxic killing of CD19+ malignant cells, with 4-1BB supporting expansion and persistence.
drug_name
Tisagenlecleucel (Kymriah)
nct_id_drug_ref
NCT05809284